The positive rate of EZH2 expression was 55.26% in poorly differentiated cancer foci, 53.85% in moderately differentiated cancer foci, and 53.33% in highly differentiated cancer foci, with no significant difference (P > 0.05). Here, EZH2 is linked to cancer.